On July 10th, with the holding of Medlab Asia 2024, a professional event for in vitro diagnostics, Bangkok, Thailand welcomed a wave of medical technology innovation, and Nanjing Bioelab landed with a group of products.
Medlab Asia is the most influential clinical laboratory medicine exhibition in Asia, bringing together over 350 exhibiting companies and more than 10000 professional visitors from more than 60 countries and regions this year. It provides a unique platform for exploring the latest developments in medicine, in vitro diagnostics, and clinical research.
With the increasing demand for medical devices in Southeast Asia, Thailand has become the largest medical device market in the region. Nevertheless, the self-sufficiency rate of medical devices is low, most of them are dependent on imports. Currently, China has become one of the four major sources of medical device imports for Thailand.
Deepening and expanding international cooperation, Bioelab has been closely monitoring the development trends and demands of the international market, launching special investigation on the Southeast Asian market, to seek new opportunities and development directions.
On the first day of the exhibition, the booth of Bioelab, H6.F56, was crowded with visitors, who showed a strong interest in our products. The series of fully automatic biochemical analyzers, blood cell analyzers, etc. received great attention from industry experts. The customers have high expectations for the performance and application potential of the products, and hope to establish a partnership with our company to explore market opportunities together.
This Thai exhibition has opened the door for Bioelab to gain new opportunities. During the exhibition, we had in-depth business exchanges with many potential partners, further consolidating the cooperation foundation in the Southeast Asian market. Once again, it proves that Bioelab is committed to providing innovative and efficient IVD solutions, and creating a healthier and more sustainable future for in vitro diagnostic testing.
In recent years, setting sail with our products multiple times, Bioelab has engaged in deep communication and cooperation negotiations with global customers and partners to jointly explore new technologies, products, and market trends in the field of IVD.
In the future, based in Nanjing and looking globally, Bioelab will continue to deeply cultivate the Southeast Asian market, and endeavor to provide high-quality and reliable in vitro diagnostic products for multiple markets around the world.
